G Tembo, M Mayuni, R Kamng'ona, L Chimgoneko, G Chiwala, S Sichone, B Galafa, F Thole, C Mkandawire, A E Chirwa, E Nsomba, V Nkhoma, C Ngoliwa, N Toto, L Makhaza, A Muyaya, E Kudowa, M Y R Henrion, D Dula, B Morton, T Chikaonda, S B Gordon, K C Jambo
BACKGROUND: Pneumococcal carriage is the primary reservoir for transmissionand a prerequisite for invasive pneumococcal disease. Pneumococcal Conjugate Vaccine 13 (PCV13) showed a 62% efficacy in protection against experimental Streptococcus pneumoniae serotype 6B (Spn6B) carriage in a controlled human infection model (CHIM) of healthy Malawian adults. We, therefore, measured humoral responses to experimental challenge and PCV-13 vaccination and determined the association with protection against pneumococcal carriage...
April 2, 2024: Vaccine